DE69130165D1 - Cyclodextrinderivate mit erhöhter wasserlöslichkeit sowie deren verwendung - Google Patents

Cyclodextrinderivate mit erhöhter wasserlöslichkeit sowie deren verwendung

Info

Publication number
DE69130165D1
DE69130165D1 DE69130165T DE69130165T DE69130165D1 DE 69130165 D1 DE69130165 D1 DE 69130165D1 DE 69130165 T DE69130165 T DE 69130165T DE 69130165 T DE69130165 T DE 69130165T DE 69130165 D1 DE69130165 D1 DE 69130165D1
Authority
DE
Germany
Prior art keywords
cyclodextrin derivatives
solubility
increased water
intranasal
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69130165T
Other languages
English (en)
Other versions
DE69130165T2 (de
Inventor
Valentino Stella
Roger Rajewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas
Original Assignee
University of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas filed Critical University of Kansas
Application granted granted Critical
Publication of DE69130165D1 publication Critical patent/DE69130165D1/de
Publication of DE69130165T2 publication Critical patent/DE69130165T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof
DE69130165T 1990-01-23 1991-01-22 Cyclodextrinderivate mit erhöhter wasserlöslichkeit sowie deren verwendung Expired - Lifetime DE69130165T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/469,087 US5134127A (en) 1990-01-23 1990-01-23 Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
PCT/US1991/000326 WO1991011172A1 (en) 1990-01-23 1991-01-22 Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof

Publications (2)

Publication Number Publication Date
DE69130165D1 true DE69130165D1 (de) 1998-10-15
DE69130165T2 DE69130165T2 (de) 1999-04-29

Family

ID=23862363

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69130165T Expired - Lifetime DE69130165T2 (de) 1990-01-23 1991-01-22 Cyclodextrinderivate mit erhöhter wasserlöslichkeit sowie deren verwendung

Country Status (10)

Country Link
US (1) US5134127A (de)
EP (1) EP0512050B1 (de)
JP (1) JP2722277B2 (de)
KR (1) KR0166088B1 (de)
AT (1) ATE170742T1 (de)
AU (1) AU646020B2 (de)
CA (1) CA2074186C (de)
DE (1) DE69130165T2 (de)
RU (1) RU2099354C1 (de)
WO (1) WO1991011172A1 (de)

Families Citing this family (747)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5262404A (en) * 1990-02-15 1993-11-16 The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
US5241059A (en) 1990-05-21 1993-08-31 Toppan Printing Co., Ltd. Cyclodextrin derivatives
JP2556236B2 (ja) * 1991-08-29 1996-11-20 田辺製薬株式会社 β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法
ATE156019T1 (de) * 1991-10-16 1997-08-15 Schering Corp Lipophile zusammensetzungen von oligosaccharid- antibiotikasalzen
DE4204315A1 (de) * 1992-02-13 1993-08-19 Consortium Elektrochem Ind Cyclodextringlycoside und verfahren zu ihrer herstellung
US5403828A (en) * 1992-08-13 1995-04-04 American Maize-Products Company Purification of cyclodextrin complexes
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US8143283B1 (en) 1993-03-01 2012-03-27 The Children's Medical Center Corporation Methods for treating blood-born tumors with thalidomide
US6114355A (en) * 1993-03-01 2000-09-05 D'amato; Robert Methods and compositions for inhibition of angiogenesis
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE4309579C3 (de) * 1993-03-24 2000-01-27 Sanol Arznei Schwarz Gmbh Pharmazeutische Zusammensetzung in Form einer Packung
DE4313408A1 (de) * 1993-04-23 1994-10-27 Boehringer Mannheim Gmbh Cyclodextrin-Biocid-Komplex
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
RU2135176C1 (ru) * 1993-12-14 1999-08-27 Эли Лилли Энд Компани Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
US5443824A (en) * 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
DE4429229A1 (de) * 1994-08-18 1996-02-22 Consortium Elektrochem Ind Cyclodextrinderivate mit mindestens einem stickstoffhaltigen Heterozyklus, ihre Herstellung und Verwendung
EP0709099A3 (de) * 1994-09-28 1996-07-24 Senju Pharma Co Wässrige Suspension zur nasalen Verabreichung enthaltend Cyclodextrin
US5468502A (en) * 1994-12-20 1995-11-21 American Home Products Corporation Ibuprofen enhancing solvent system
BE1008978A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
DE19505263A1 (de) * 1995-02-16 1996-08-22 Consortium Elektrochem Ind Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
AU5774796A (en) * 1995-06-13 1997-01-09 Dyer, Alison Margaret Pharmaceutical compositions containing lornoxicam and cyclod extrin
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
HUT75956A (en) * 1995-11-29 1997-05-28 Cyclolab Pharmaceutical composition containing thyroxine
GB9605705D0 (en) 1996-03-19 1996-05-22 Pfizer Ltd Therapeutic agents
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
DE69740095D1 (de) * 1996-11-05 2011-02-17 Childrens Medical Center Thalidomide und Dexamethason für die Behandlung von Tumors
KR100411289B1 (ko) * 1996-11-29 2004-02-14 주식회사 포스코 회전장애 이성질체의 분리에 유용한 6-알릴디메틸실릴-2,3-디에 틸-베타-시클로덱스트린 및 그 제조방법
KR100435426B1 (ko) * 1996-11-29 2004-08-16 주식회사 포스코 구조 이성질체의 분리에 유용한 6-디메틸옥틸실릴-2,3-디에틸-베타-시클로덱스트린 및 그 제조방법
DE19713092A1 (de) * 1997-03-27 1998-10-01 Wacker Chemie Gmbh Komplexe aus Gamma-Cyclodextrin und Retinol bzw. Retinol-Derivaten sowie Verfahren zu ihrer Herstellung und ihre Verwendung
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
JP4439596B2 (ja) * 1997-06-13 2010-03-24 サイデクス ファーマシューティカルズ、 インク. 長期の貯蔵寿命を有する、極性薬物又は極性プロドラッグを含有する医薬組成物、及びその製造方法
GB9713149D0 (en) * 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
DK0889056T3 (da) * 1997-07-01 2006-07-17 Pfizer Prod Inc Process for making a cyclodextrin
US6391862B1 (en) * 1997-10-14 2002-05-21 The Texas A&M University System Chiral resolving agents for enantioseparations
AU759280C (en) * 1998-02-23 2004-01-22 Cyclops, Ehf High-energy cyclodextrin complexes
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6673828B1 (en) 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
DE19825486C2 (de) * 1998-06-08 2000-07-06 Stockhausen Chem Fab Gmbh Wasserabsorbierende Polymere mit supramolekularen Hohlraummolekülen, Verfahren zu deren Herstellung und deren Verwendung
NZ330726A (en) * 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
US20020198174A1 (en) * 2001-05-07 2002-12-26 Allergan Sales, Inc. Disinfecting and solubilizing steroid compositions
AU757896B2 (en) 1998-09-02 2003-03-13 Allergan, Inc. Preserved cyclodextrin-containing compositions
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
EP1143796A4 (de) 1999-01-21 2002-03-20 Bristol Myers Squibb Co KOMPLEX EINES RAS-FARNESYLTRANSFERASEINHIBITORS UND SULFOBUTYLETHER-7--g(b)-CYCLODEXTRIN ODER 2-HYDROXYPROPYL--g(b)-CYCLODEXTRIN SOWIE EIN VERFAHREN
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
DE19939662A1 (de) 1999-08-20 2001-02-22 Stockhausen Chem Fab Gmbh Wasserabsorbierende Polymere mit Hohlraumverbindungen, Verfahren zur deren Herstellung und deren Verwendung
GB9921958D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
GB9921954D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
US6689378B1 (en) 1999-12-28 2004-02-10 Kimberly-Clark Worldwide, Inc. Cyclodextrins covalently bound to polysaccharides
WO2001047569A1 (en) * 1999-12-28 2001-07-05 Kimberly-Clark Worldwide, Inc. Superabsorbent polymers
US6677256B1 (en) 1999-12-28 2004-01-13 Kimberly-Clark Worldwide, Inc. Fibrous materials containing activating agents for making superabsorbent polymers
SK282717B6 (sk) * 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
CN1420776A (zh) * 2000-03-31 2003-05-28 塞尔基因公司 环氧合酶-2活性的抑制
BR0110679A (pt) * 2000-04-28 2004-04-20 Univ Dublin Derivados anfìfilos macrocìclicos e seus análogos
SI1278549T1 (sl) 2000-05-02 2009-04-30 Theravance Inc Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
ES2215129T3 (es) 2000-05-26 2004-10-01 Pfizer Inc. Derivados de triazolil tropano como modulares de ccr5.
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6420557B1 (en) 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
ES2290091T3 (es) * 2000-11-30 2008-02-16 The Children's Medical Center Corporation Sintesis de enantiomeros de 4-amino-talidomida.
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
JP2005503446A (ja) 2001-01-11 2005-02-03 イーストマン ケミカル カンパニー シクロデキストリンスルホネート、ゲスト包接錯体、その製造方法及び関連物質
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EA007184B1 (ru) 2001-04-10 2006-08-25 Пфайзер Инк. Производные пиразола для лечения инфекции вируса иммунодефицита человека (вич)
BR0102252B1 (pt) * 2001-04-10 2013-10-22 Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
CZ20032959A3 (cs) * 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1269994A3 (de) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
EA008072B1 (ru) * 2001-12-03 2007-02-27 Новацея, Инк. Фармацевтические составы, содержащие соединения активного витамина d
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
IL162870A0 (en) 2002-02-01 2005-11-20 Pfizer Prod Inc Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor
CA2475712C (en) 2002-02-11 2009-11-24 Simon Bailey Nicotinamide derivatives useful as pde4 inhibitors
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
US20030164219A1 (en) * 2002-02-20 2003-09-04 Joerg Brahm Headliner/duct assembly and welding process therefor
CA2477044A1 (en) * 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic formulation with gum system
MXPA04008173A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
KR100451485B1 (ko) * 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
DE10215942A1 (de) * 2002-04-11 2003-10-23 Bayer Ag Wässrige Formulierungen von (2-Hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorbutan-1-sulfonat
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
EP2915533B1 (de) 2002-05-17 2017-09-13 Celgene Corporation Pharmazeutische Zusammensetzungen zur Behandlung von Krebs
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1556033A4 (de) * 2002-05-17 2006-05-31 Celgene Corp Verfahren und zusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zur behandlung und versorgung von krebs und anderen erkrankungen
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US6818662B2 (en) * 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
TWI307626B (en) * 2002-08-20 2009-03-21 Bristol Myers Squibb Co Aripiprazole complex formulation and method
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US6884790B2 (en) * 2002-09-09 2005-04-26 Josef Pitha Verifiable absorption drug delivery form based on cyclodextrins
GB0221169D0 (en) 2002-09-12 2002-10-23 Univ Bath Crystal
AU2003275329B2 (en) * 2002-09-13 2008-04-03 Cydex Pharmaceuticals, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
AU2003228509B2 (en) * 2002-10-15 2008-06-26 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
EP1900369A1 (de) 2002-10-15 2008-03-19 Celgene Corporation Verfahren zur Verwendung von und Zusammensetzungen mit immunmodulatorischen Verbindungen für die Therapie und Behandlung des myelodysplastischen Syndroms
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7001893B2 (en) * 2002-10-28 2006-02-21 Council Of Scientific And Industrial Research Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof
BR0316057A (pt) 2002-11-06 2005-09-20 Celgene Corp Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
KR20050085563A (ko) 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
EA008829B1 (ru) * 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
EA009123B1 (ru) * 2003-01-14 2007-10-26 Тева Фармасьютикал Индастриз, Лтд. Парентеральные композиции пептидов для лечения системной красной волчанки
CN1761477A (zh) * 2003-01-14 2006-04-19 特瓦制药工业有限公司 治疗系统性红斑狼疮的肽的胃肠道外制剂
EP1460064A1 (de) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide als beta-2 Agonisten
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
DK3604537T3 (da) 2003-06-13 2022-02-28 Alnylam Europe Ag Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
BRPI0414105B8 (pt) 2003-09-03 2021-05-25 Askat Inc compostos de benzimidazolona com atividade agonista do receptor 5-ht4
US7875630B2 (en) 2003-09-03 2011-01-25 Glaxo Group Limited Process salts compositions and use
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
WO2005023308A1 (en) * 2003-09-05 2005-03-17 Maxygen Holdings Ltd. Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
BRPI0414343A (pt) 2003-09-12 2006-11-07 Pfizer combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina
ATE380813T1 (de) 2003-10-03 2007-12-15 Pfizer Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen
AU2004283431B2 (en) * 2003-10-10 2009-09-10 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
US7129042B2 (en) * 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
CN1901911A (zh) * 2003-11-06 2007-01-24 细胞基因公司 使用沙利度胺治疗和控制癌症和其它疾病的组合物和方法
SG148198A1 (en) 2003-11-21 2008-12-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
WO2005055952A2 (en) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Synergistic anti-cancer compositions
CA2548917C (en) 2003-12-11 2014-09-23 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2004312096A1 (en) * 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
AU2005214153B2 (en) 2004-01-22 2008-09-18 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
CA2553293C (en) 2004-01-22 2010-12-14 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
US7449462B2 (en) 2004-01-22 2008-11-11 Pfizer, Inc. Triazole derivatives which inhibit vasopressin antagonistic activity
CN1921893B (zh) 2004-02-24 2011-11-09 综合医院公司 催化放射性氟化法
WO2005088655A1 (en) * 2004-03-12 2005-09-22 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
US7629358B2 (en) 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
AU2005223483B2 (en) 2004-03-18 2009-04-23 Zoetis Llc N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
JP2007530544A (ja) * 2004-03-22 2007-11-01 セルジーン・コーポレーション 皮膚疾患又は障害を治療及び管理するための免疫調節化合物の使用方法及びそれを含む組成物
PL1730103T3 (pl) 2004-03-23 2010-10-29 Pfizer Pochodne formamidu użyteczne jako adrenoreceptor
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
EP1744749A4 (de) * 2004-04-14 2009-04-22 Celgene Corp Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen
CA2563207A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
CN102174076A (zh) 2004-04-15 2011-09-07 普罗特奥里克斯公司 用于抑制蛋白酶体酶的化合物
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
CN101098678A (zh) * 2004-04-23 2008-01-02 锡德克斯公司 含有磺基烷基醚环糊精的dpi制剂
EP1745029A1 (de) 2004-04-30 2007-01-24 Warner-Lambert Company LLC Substituierte morpholinverbindungen zur behandlung von erkrankungen des zentralen nervensystems
EP1750776A2 (de) 2004-04-30 2007-02-14 Alnylam Pharmaceuticals Inc. Oligonukleotide mit c5-modifiziertem pyrimidin
CN1980574A (zh) * 2004-05-06 2007-06-13 锡德克斯公司 包含舍曲林和磺基烷基醚环糊精的掩味的制剂
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
PL2030981T3 (pl) * 2004-05-10 2014-12-31 Onyx Therapeutics Inc Związki do enzymatycznej inhibicji proteasomu
EP1595881A1 (de) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EP1758891A2 (de) 2004-06-15 2007-03-07 Pfizer Japan Inc. Benzimidazoloncarbonsäurederivate
US20070213270A1 (en) * 2004-06-16 2007-09-13 Costantino Henry R Peptide yy formulations having increased stability and resistance to microbial agents
PL1768966T3 (pl) 2004-06-17 2012-08-31 Infinity Discovery Inc Związki i sposoby hamowania oddziaływania białek BCL z partnerami wiążącymi
AU2005273612B2 (en) 2004-08-12 2010-10-14 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
ATE463486T1 (de) 2004-08-26 2010-04-15 Pfizer Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
ZA200702382B (en) * 2004-09-03 2008-08-27 Celgene Corp Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EP1809618B1 (de) 2004-09-21 2013-07-17 Marshall Edwards, Inc. Chromanderivate, medikamente und anwendung in der therapie
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
AU2005287865B2 (en) 2004-09-21 2012-02-16 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
US20060078955A1 (en) * 2004-10-13 2006-04-13 Lin-Zhi International Method for retrieving delta9-THC from oral fluid
RU2349334C2 (ru) * 2004-10-26 2009-03-20 Виктор Олександровыч Рыбчук Лекарственное средство седативного и спазмолитического действия и способ его изготовления (варианты)
EP1811992A2 (de) * 2004-10-28 2007-08-01 Celgene Corporation Verfahren und zusammensetzungen unter verwendung von pde4-modulatoren zur behandlung und versorgung von verletzungen des zentralen nervensystems
MX2007005290A (es) 2004-11-02 2007-07-09 Pfizer Derivados de sulfonilbencimidazol.
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
CA2589921C (en) * 2004-12-07 2016-01-26 Proteolix, Inc. Composition comprising a cyclodextrin and a proteasome inhibitor
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
DE102004060927B3 (de) * 2004-12-17 2006-02-16 Schwan-Stabilo Schwanhäusser Gmbh & Co. Kg Behälter für mindestens einen länglichen Gegenstand
EP1674098A1 (de) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
AU2006214236A1 (en) * 2005-02-16 2006-08-24 Alza Corporation Apparatus and method for transdermal delivery of erythropoetin-based agents
KR20080016531A (ko) * 2005-02-18 2008-02-21 서피스 로직스, 인크. 약동학적으로 개선된 화합물
CN101287468A (zh) * 2005-02-18 2008-10-15 表面线段公司 制备包含官能性残基或基团的药动学改善的化合物的方法以及包含所述化合物的药用组合物
CA2614223A1 (en) 2005-02-24 2006-08-31 Dr Pharma Nova, Llc A registry method and control system for dea schedule ii-v medicines
BRPI0608436A2 (pt) 2005-03-17 2009-12-29 Pfizer derivados de n-(n-sulfonilaminometil) ciclopropanocarboxamida utilizáveis para o tratamento de dor
ATE412648T1 (de) 2005-03-21 2008-11-15 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
JP2008534611A (ja) 2005-03-30 2008-08-28 シェーリング コーポレイション 抗コリン作用薬、コルチコステロイドおよび長時間作用性βアゴニストを合わせる薬物および方法
CA2851079A1 (en) * 2005-04-15 2006-10-26 Albert Einstein College Of Medicine Of Yeshiva University Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy
CA2602022C (en) 2005-04-19 2016-03-22 Gabriel Stavros Panayi Binding immunoglobulin protein (bip) for prevention or treatment of bone conditions or diseases
WO2007124250A2 (en) 2006-04-21 2007-11-01 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
CA2606064A1 (en) * 2005-04-24 2006-11-02 Wyeth Methods for modulating bladder function
JP2008540396A (ja) 2005-05-04 2008-11-20 ファイザー・リミテッド 癌およびc型肝炎などのウイルス感染を治療するためのトール様受容体調節薬としての2−アミド−6−アミノ−8−オキソプリン誘導体
WO2006124726A2 (en) * 2005-05-12 2006-11-23 The General Hospital Corporation Novel biotinylated compositions
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
BRPI0612032A2 (pt) * 2005-06-13 2010-10-13 Cargill Inc complexos de inclusão de ciclodextrina e métodos de preparação dos mesmos
CN101223183A (zh) * 2005-06-13 2008-07-16 嘉吉公司 环糊精包合复合物及其制备方法
CA2611917A1 (en) * 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited Injection
ES2338699T3 (es) 2005-06-15 2010-05-11 Pfizer Limited Arilpirazoles sustituidos para uso contra parasitos.
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US20060287301A1 (en) * 2005-06-17 2006-12-21 Mcnair Douglas Novel formulations for phenothiazines, including fluphenazine and its derivatives
AU2006265019B2 (en) * 2005-06-30 2011-10-13 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
AU2006269498A1 (en) * 2005-07-06 2007-01-18 Edgar, Mark Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009531A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
CA2899923A1 (en) 2005-08-31 2007-03-08 Celgene Corporation Isoindole-imide compounds and compositions comprising and methods of using the same
US8580814B2 (en) * 2006-04-03 2013-11-12 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US7744904B1 (en) 2005-09-26 2010-06-29 B.B. Scientific L.L.C. Stabilization of Clostridium botulinum neurotoxin complex
AU2013200204B9 (en) * 2005-09-30 2015-03-05 Lundbeck Llc Novel parenteral carbamazepine formulation
US20100204178A1 (en) * 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
EP1928464B1 (de) 2005-09-30 2014-05-14 Lundbeck Inc. Neue parenterale carbamazepin-formulierung
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
AU2011204957B2 (en) * 2005-10-26 2013-12-05 Cydex Pharmaceuticals, Inc Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
EP2581078B1 (de) * 2005-10-26 2014-12-10 Cydex Pharmaceuticals, Inc. Sulfoalkylethercyclodextrin- Zusammensetzungen und deren Herstellungsverfahren
CN100503647C (zh) 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
PT1948678E (pt) * 2005-11-09 2013-07-16 Onyx Therapeutics Inc Compostos para inibição de enzimas
CA2626122A1 (en) * 2005-11-15 2007-05-24 Baxter International, Inc. Compositions comprising lipoxygenase inhibitors and cyclodextrin
CA2631014C (en) * 2005-11-28 2015-04-28 Vernon D. Rowe Compositions useful for reducing nephrotoxicity and methods of use thereof
EA017290B1 (ru) 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед Композиции на основе ганаксолона
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
US20070232537A1 (en) * 2005-12-19 2007-10-04 Nastech Pharmaceutical Company Inc. Intranasal pyy formulations with improved transmucosal pharmacokinetics
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
JP2009526860A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 安定したコルチコステロイド混合物
CL2007000773A1 (es) * 2006-03-24 2008-01-25 Wyeth Corp Uso de compuestos derivados de diazepina condensada para el tratamiento de un desorden cognitivo como add o adhd;o su uso para tratar spm o pmdd.
BRPI0709163A2 (pt) * 2006-03-24 2011-06-28 Wyeth Corp tratamento da dor
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
TW200806298A (en) * 2006-03-24 2008-02-01 Wyeth Corp Methods for modulating bladder function
MX2008012212A (es) * 2006-03-24 2008-10-02 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines.
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
KR20090037388A (ko) 2006-04-18 2009-04-15 이케이알 테라퓨틱스, 인코포레이티드 미리 혼합된 즉시 사용가능한 iv 볼루스 조성물 및 이의 사용 방법
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
CN100374468C (zh) * 2006-05-25 2008-03-12 重庆通量精细化工有限公司 水溶性磺烷基醚-β-环糊精的合成工艺
AU2007258280B2 (en) * 2006-06-12 2013-05-02 Sunesis Pharmaceuticals, Inc. Compounds and compositions for treatment of cancer
AU2006344479A1 (en) * 2006-06-13 2007-12-21 Cargill, Incorporated Large-particle cyclodextrin inclusion complexes and methods of preparing same
US7691852B2 (en) * 2006-06-19 2010-04-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
WO2008003317A1 (en) * 2006-07-03 2008-01-10 Genmab A/S Prevention of rash in patients undergoing anti-egfr therapy
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
WO2008012538A2 (en) 2006-07-25 2008-01-31 The Secretary Of State For Defence Live vaccine strains of francisella
MX344865B (es) 2006-08-02 2016-12-19 Sunesis Pharmaceuticals Inc Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.
JP5270545B2 (ja) 2006-08-03 2013-08-21 タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ フラッシングのないナイアシン類似体およびそれらの使用法
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
EP2061459B1 (de) 2006-08-23 2012-12-26 Intellect Neurosciences Inc. 3-(3-indolyl)propionsäure-calciumsalz und verfahren zur herstellung von 3-(3-indolyl)propionsäurefreier säure daraus
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CA2664251A1 (en) 2006-09-12 2008-03-20 Cephalin Pharmaceuticals Inc. Isovaline for treatment of pain
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
EP2061458B1 (de) * 2006-09-15 2014-12-10 Regents of the University of Minnesota Topiramatzubereitungen und verfahren zu ihrer verwendung
EP2380566A3 (de) 2006-09-15 2012-04-11 Stevia APS Verwendung von Steviol oder Isosteviol in der Behandlung von Insulinresistenz oder von mit Insulinresistenz assoziierten Krankheiten
ATE512969T1 (de) 2006-09-21 2011-07-15 Raqualia Pharma Inc Benzimidazolderivate als selektive säurepumpenhemmer
DK2428513T3 (en) 2006-09-26 2017-08-21 Celgene Corp 5-substituted quinazolinone derivatives as anti-cancer agents
EP2076287A2 (de) 2006-10-12 2009-07-08 Wyeth Verfahren und zusammensetzungen mit verringerter opaleszenz
DK2076508T3 (da) 2006-10-18 2011-02-21 Pfizer Prod Inc Biaryl-ether-urinstof-forbindelser
JP2010512305A (ja) 2006-10-23 2010-04-22 ファイザー株式会社 置換フェニルメチルビシクロカルボキシアミド化合物
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
KR20090087079A (ko) * 2006-11-21 2009-08-14 노파르티스 아게 벤조디아제핀 구조의 rsv 억제제를 포함하는 안정한 비경구 제형
WO2008065142A1 (en) * 2006-11-29 2008-06-05 N.V. Organon Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
US20100160623A1 (en) * 2006-12-27 2010-06-24 Cargill, Incorporated Cyclodextrin inclusion complexes and methods of preparing same
KR20090127326A (ko) 2007-03-02 2009-12-10 와이어쓰 폴리펩티드의 생산을 위한 세포 배양물 중에서 구리 및 글루타메이트의 용도
ES2373867T3 (es) * 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
WO2011084703A2 (en) 2009-12-21 2011-07-14 Advanced Liquid Logic, Inc. Enzyme assays on a droplet actuator
DK2152078T3 (da) 2007-04-27 2021-02-08 Cydex Pharmaceuticals Inc Formuleringer indeholdende clopidogrel og sulfoalkylethercyclodextrin og anvendelsesfremgangsmåder
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US20080283693A1 (en) * 2007-05-15 2008-11-20 Evans Michael J F Propulsion apparatus and system
TWI364290B (en) 2007-05-25 2012-05-21 Ipsen Pharma Sas Melanocortin receptor ligands modifled with hydantoin
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
TWI428132B (zh) * 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
WO2009018326A2 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Soluble pyrone analogs methods and compositions
WO2009020590A1 (en) * 2007-08-07 2009-02-12 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
CA2697495C (en) 2007-09-05 2013-02-05 Pfizer Limited Xinafoate salt of n4-[(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
CN104211684A (zh) 2007-09-26 2014-12-17 细胞基因公司 6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
KR20170040374A (ko) * 2007-10-04 2017-04-12 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US8518872B2 (en) * 2007-10-22 2013-08-27 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
WO2009105256A2 (en) * 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
JP2011513201A (ja) * 2008-02-28 2011-04-28 武田薬品工業株式会社 医薬組成物
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
GB2458473A (en) 2008-03-17 2009-09-23 Imuthes Ltd 3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
US7635773B2 (en) * 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CA2722426A1 (en) * 2008-04-30 2009-11-05 Neutron Row Methods of using corticotropin-releasing factor for the treatment of cancer
WO2009137611A2 (en) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Treatment of pulmonary fungal infection with voriconazole via inhalation
EP2303229A1 (de) * 2008-06-16 2011-04-06 Debiopharm S.A. Konzentrierte oxaliplatin-lösung und herstellungsverfahren dafür
US20100022635A1 (en) * 2008-07-28 2010-01-28 University Of Kansas Heat shock protein 90 inhibitor dosing methods
US8518952B2 (en) 2008-08-06 2013-08-27 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors
US20120039917A1 (en) 2008-08-29 2012-02-16 Alan James Husband Immunomodulating activities
EP2163253B1 (de) 2008-09-15 2013-07-17 ULLRICH, Oliver Extrakte von der Pflanze Hornstedtia scyphifera und deren immunsuppressive Wirkungen
MX2011004225A (es) 2008-10-21 2011-06-21 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
US20100130598A1 (en) * 2008-10-22 2010-05-27 Novogen Research Pty Ltd. Methods for inducing programmed cell death
JP5864257B2 (ja) 2008-10-24 2016-02-17 サレプタ セラピューティクス, インコーポレイテッド Dmdのための複数のエキソンスキッピング組成物
MX2011004470A (es) 2008-10-29 2011-05-31 Celgene Corp Compuestos de isoindolina para uso en el tratamiento de cancer.
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
CA2743419C (en) * 2008-11-15 2017-02-14 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
RU2528406C2 (ru) 2008-11-21 2014-09-20 Раквалиа Фарма Инк. Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
CN102317261B (zh) 2008-12-16 2015-11-25 桑诺维恩药品公司 三重再摄取抑制剂及其应用方法
KR20110101212A (ko) 2008-12-17 2011-09-15 제넨테크, 인크. C형 간염 바이러스 조합 요법
SG10201504789RA (en) * 2008-12-31 2015-07-30 Sunesis Pharmaceuticals Inc Method Of Preparing (+)-1,4-Dihydro-7-[(3s,4s)-3methoxy-4-(Methylamino)-1-Pyrrolidinyl]-4-Oxo-1-(2-Thiazolyl)-1,8-Naphthyridine-3-Carboxylic Acid
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
WO2010082813A1 (en) 2009-01-13 2010-07-22 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam Method of treating cancer
EP2387580B1 (de) 2009-01-14 2014-08-13 Novacta Biosystems Limited Deoxyactagardinderivate
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
JP5731407B2 (ja) 2009-02-04 2015-06-10 ノヴァクタ バイオシステムズ リミティッド アクタガルジン誘導体
CA2750123A1 (en) 2009-02-10 2010-08-19 Celgene Corporation Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
SG173639A1 (en) 2009-02-11 2011-09-29 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof
US20120053159A1 (en) 2009-02-11 2012-03-01 Muller George W Isotopologues of lenalidomide
EP2400959A1 (de) 2009-02-27 2012-01-04 Sunesis Pharmaceuticals, Inc. Verfahren zur verwendung von sns-595 für die behandlung von krebspatienten mit verminderter brca2-aktivität
EP2406281B1 (de) 2009-03-12 2016-02-17 Haase Investments UG Varianten des knochenmorphogenetischen proteins 2 (bone morphogenetic protein 2, bmp2) mit reduzierter bmp-antagonistischer empfindlichkeit
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2233502A1 (de) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
UA103792C2 (uk) * 2009-04-14 2013-11-25 Елі Ліллі Енд Компані Похідна бензодіазепіну для лікування гемопоетичної неоплазми та лейкозу
DK3100728T3 (da) 2009-05-13 2020-02-17 Cydex Pharmaceuticals Inc Farmaceutiske sammensætninger omfattende prasugrel og cyclodextrin-derivativ og fremgangsmåder til fremstilling og brug af samme
JP5645816B2 (ja) 2009-05-25 2014-12-24 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
KR20120018813A (ko) 2009-05-29 2012-03-05 화이자 리미티드 글루코코티코이드 수용체 작용제
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
CN102458114A (zh) * 2009-05-29 2012-05-16 锡德克斯药物公司 包含环糊精衍生物的可注射美法仑组合物及其制备和使用方法
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
CA2764808A1 (en) 2009-06-10 2010-12-16 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
EP2266563A1 (de) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Verwendung von Opiodrezeptorantagonisten zur akuten Behandlung von paraphilischen Erregungszuständen
AU2010260208B2 (en) 2009-06-16 2014-11-13 Bristol-Myers Squibb Holdings Ireland Unlimited Company Dosage forms of apixaban
JP2012530740A (ja) 2009-06-24 2012-12-06 エヴァンス−フリーク,ステファン がん治療の為のコルチコトロピン放出因子の使用方法
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
EP2467379B1 (de) 2009-08-19 2016-03-02 ratiopharm GmbH Verfahren zur Herstellung von Coevaporaten und Komplexen von Voriconazol und Cyclodextrin
US20120172350A1 (en) 2009-09-11 2012-07-05 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
EP3199634A1 (de) 2009-11-13 2017-08-02 Sarepta Therapeutics, Inc. Antivirale antisense-verbindung und verfahren zur behandlung von influenzavirusinfektion
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
CN102781443A (zh) 2009-11-19 2012-11-14 细胞基因公司 用于治疗结节病的阿普斯特
WO2011064558A2 (en) 2009-11-30 2011-06-03 Cipla Limited Pharmaceutical composition
CN102762575B (zh) 2009-12-04 2015-04-15 桑诺维恩药品公司 多环化合物及其使用方法
WO2011075699A2 (en) 2009-12-18 2011-06-23 Sunovion Pharmaceuticals Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
WO2011079091A1 (en) 2009-12-22 2011-06-30 Celgene Corporation (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
ME02186B (me) 2009-12-23 2016-02-20 Takeda Pharmaceuticals Co Fuzionisani heteroaromatski pirolidinoni kao syk inhibitori
EP2851070A1 (de) 2010-01-05 2015-03-25 Celgene Corporation Kombination von Lenalidomid und Artesunat/Artemison zur Behandlung von Krebs
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
EP2531519A1 (de) 2010-02-02 2012-12-12 Novacta Biosystems Limited Lantibiotische salze
MX337169B (es) 2010-02-11 2016-02-16 Celgene Corp Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.
CA2789606A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues as opioid receptor agonists
MA34133B1 (fr) 2010-03-01 2013-04-03 Onyx Therapeutics Inc Composes pour inhibiteurs de l'immunoproteasome
MX2012010367A (es) 2010-03-12 2012-11-23 Celgene Corp Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor.
EP2545173A2 (de) 2010-03-12 2013-01-16 Sarepta Therapeutics, Inc. Antisense-modulation von nukleären hormonrezeptoren
US8697646B2 (en) 2010-04-07 2014-04-15 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
CA3090304A1 (en) 2010-05-13 2011-11-17 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
NZ604498A (en) 2010-05-26 2014-10-31 Neurophyxia B V 2-iminobiotin formulations and uses thereof
AU2011258217B2 (en) 2010-05-26 2016-12-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
US8450316B2 (en) 2010-06-24 2013-05-28 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
WO2011163612A1 (en) 2010-06-24 2011-12-29 Trustees Of Tufts College Niacin mimetics, and methods of use thereof
CA2802929C (en) 2010-06-29 2019-01-08 David Monteith Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin
NL2005052C2 (en) 2010-07-07 2012-01-10 Caroline Haaften Xanthanodien for the treatment of cancer.
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
ES2526675T3 (es) 2010-07-09 2015-01-14 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
JP5830534B2 (ja) 2010-07-09 2015-12-09 ファイザー・リミテッドPfizer Limited 化合物
ES2526541T3 (es) 2010-07-12 2015-01-13 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
EP2593431B1 (de) 2010-07-12 2014-11-19 Pfizer Limited N-sulfonylbenzamide als inhibitoren von spannungsabhängigen natriumkanälen
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013536165A (ja) 2010-07-12 2013-09-19 ファイザー・リミテッド 痛みの処置のためのnav1.7阻害薬としてのスルホンアミド誘導体
EP2409699B1 (de) 2010-07-23 2014-04-30 Combino Pharm, S.L. Stabile Voriconazole-enthaltende Zusammensetzungen
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
JP5820476B2 (ja) 2010-08-24 2015-11-24 アルギアックス ファルマコウティカルス ゲーエムベーハーALGIAX Pharmaceuticals GmbH レフルノミドおよびマロノニトリラマイドの新規の使用
AU2011294888B2 (en) 2010-08-24 2015-06-18 Imperial Innovations Limited Glycodendrimers of polypropyletherimine
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
PT2632451T (pt) 2010-10-29 2017-12-14 Algiax Pharmaceuticals Gmbh Utilização de malononitrilamidas na dor neuropática
EP2635121B1 (de) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoidverbindungen und verfahren zur behandlung von krebs
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
EP2663549B1 (de) 2011-01-10 2018-03-14 Celgene Corporation Phenethylsulfonisoindolinderivate als pde-4- und/oder zytokin-hemmer
US8765760B2 (en) 2011-01-11 2014-07-01 Sunovion Pharmaceuticals, Inc. [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
WO2012100142A2 (en) 2011-01-20 2012-07-26 Cornell University Treatments for retinal disorders
CN103415292A (zh) 2011-01-26 2013-11-27 阿勒根公司 用于治疗眼科病症的雄性激素组合物
WO2012106299A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012148548A1 (en) 2011-02-25 2012-11-01 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
SG192946A1 (en) 2011-03-11 2013-09-30 Celgene Corp Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
EP2683384B1 (de) 2011-03-11 2015-12-09 Celgene Corporation Verfahren zur behandlung von krebs mit 3-(5-amino-2-methyl-4-oxo-4h-chinazolin-3-yl)-piperidin-2,6-dion
US20140038967A1 (en) 2011-03-17 2014-02-06 Algiax Pharmaceuticals Gmbh Novel use for imidazotriazinones
WO2012123353A1 (en) 2011-03-17 2012-09-20 Algiax Pharmaceuticals Gmbh Novel use of benzofuranylsulfonates
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
RU2464042C1 (ru) * 2011-03-31 2012-10-20 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
MX2013011612A (es) 2011-04-05 2013-10-17 Pfizer Ltd Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasa relacionados con tropomiosina.
WO2012138214A1 (en) 2011-04-08 2012-10-11 Brewster Lizzy Maritza Beta-guanidinopropionic acid for the treatment of hypertension
WO2012149299A2 (en) 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
RU2616978C2 (ru) 2011-05-18 2017-04-19 Раквалиа Фарма Инк. Полиморфная форма 4-{ [4-({ [4-(2,2,2-трифторэтокси)-1,2-бензизоксазол-3-ил]окси} метил)пиперидин-1-ил]метил} -тетрагидро-2н-пиран-4-карбоновой кислоты
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠(olopatadine)眼用組成物
US9480755B2 (en) * 2011-06-03 2016-11-01 Ratiopharm Gmbh Pharmaceutical composition comprising dapagliflozin and cyclodextrin
EP2720723B1 (de) 2011-06-15 2018-04-11 Synthon BV Stabilisierte voriconazolzusammensetzung
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
EP2723739B1 (de) 2011-06-22 2016-08-24 Takeda Pharmaceutical Company Limited Substituierte 6-aza-isoindolin-1-on-derivate
WO2013009927A2 (en) 2011-07-11 2013-01-17 Advanced Liquid Logic, Inc. Droplet actuators and techniques for droplet-based assays
ES2564366T3 (es) 2011-07-13 2016-03-22 Pfizer Limited Análogos de encefalina
AU2012284259A1 (en) 2011-07-15 2014-03-06 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
RU2014102935A (ru) 2011-08-02 2015-09-10 Пфайзер Инк. Кризотиниб для применения в лечении рака
EP2739274A1 (de) 2011-08-02 2014-06-11 Pensieve Biosciences Cyprus Limited Behandlung von kognitiver störung
EP2561863A1 (de) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Pharmazeutische Zusammensetzungen mit Voriconazol
LT2758052T (lt) 2011-09-18 2018-04-10 Euro-Celtique S.A. Farmacinė kompozicija, apimanti hdac inhibitorių ir ciklopolisacharidą
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
AU2012328034B2 (en) 2011-10-26 2015-04-23 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
ES2648901T3 (es) 2011-10-28 2018-01-08 Inhibitaxin Limited Derivados de piridazina útiles en terapia
HUE038369T2 (hu) 2011-12-08 2018-10-29 Sarepta Therapeutics Inc Humán LMNA-t célzó oligonukleotid-analógok
JP6058023B2 (ja) 2011-12-15 2017-01-11 ファイザー・リミテッドPfizer Limited スルホンアミド誘導体
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
CA2859873A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
CA2859876A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
BR112014015308A2 (pt) 2011-12-23 2017-06-13 Novartis Ag compostos para inibição da interação de bcl2 com contrapartes de ligação
CA2859869A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
US9126980B2 (en) 2011-12-23 2015-09-08 Novartis Ag Compounds for inhibiting the interaction of BCL2 with binding partners
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β-環糊精之藥物製劑
US20150291514A1 (en) 2012-01-04 2015-10-15 Pfizer Limted N-Aminosulfonyl Benzamides
IL298436B1 (en) 2012-01-23 2024-03-01 Sage Therapeutics Inc Pharmaceutical preparations that include allopregnanolone
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
ES2548228T3 (es) 2012-02-03 2015-10-15 Pfizer Inc Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio
US10189825B2 (en) 2012-02-08 2019-01-29 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
TW201336527A (zh) 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
PT2814849T (pt) 2012-02-15 2020-03-04 Cydex Pharmaceuticals Inc Processo de fabrico para derivados de ciclodextrina
ES2671608T3 (es) 2012-02-21 2018-06-07 Celgene Corporation Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona
JP2015508846A (ja) 2012-02-28 2015-03-23 サイデックス・ファーマシューティカルズ・インコーポレイテッド アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
EP2819691A1 (de) 2012-03-02 2015-01-07 Erasmus University Medical Center Rotterdam Verfahren zur aktivierung von retroviren in latenten infizierten zellen und verbindungen zur verwendung darin
ES2621220T3 (es) 2012-03-06 2017-07-03 Pfizer Inc. Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
EP2831122B1 (de) 2012-03-30 2016-02-03 SapioTec GmbH Anthocyanidin-komplex
ES2620080T3 (es) 2012-03-30 2017-06-27 Sapiotec Gmbh Uso de delfinidina contra Staphylococcus aureus
WO2013156232A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of benzofuranylsulfonates in neuropathic pain
WO2013156231A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of imidazotriazinones in neuropathic pain
IN2014MN02236A (de) 2012-05-11 2015-07-24 Cipla Ltd
US9315489B2 (en) 2012-05-15 2016-04-19 Novartis Ag Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
DK2861579T5 (da) 2012-05-15 2022-10-24 Novartis Ag Benzamidderivater til at hæmme aktiviteten af ABL1, ABL2 og BCR-ABL1
CA2871332A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
CA2871715A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
WO2013183985A1 (en) 2012-06-05 2013-12-12 Erasmus University Medical Center Rotterdam Method of treating cognitive impairment and compounds for use therein
ES2699810T3 (es) 2012-06-29 2019-02-12 Celgene Corp Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon
US9309283B2 (en) 2012-07-09 2016-04-12 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
MX2015000813A (es) 2012-07-18 2015-09-07 Onyx Therapeutics Inc Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
CN108938642A (zh) 2012-08-09 2018-12-07 细胞基因公司 免疫相关和炎性疾病的治疗
CN104703978B (zh) 2012-08-09 2018-05-11 细胞基因公司 化合物的盐和固体形式及其组合物和使用方法
SG10201701057SA (en) 2012-08-09 2017-03-30 Celgene Corp Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
WO2014036427A1 (en) 2012-08-31 2014-03-06 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
EP2909212B1 (de) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituierte 1,4-dihydropyrazolo[4,3-b]indole
BR112015005243A2 (pt) 2012-09-10 2017-07-04 Celgene Corp métodos para o tratamento de câncer de mama localmente avançado
US9533989B2 (en) 2012-09-18 2017-01-03 Ziarco Pharma Ltd. Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドPfizer Limited ピロロ[3,2−c]ピリジントロポミオシン関連キナーゼ阻害剤
JP2015531393A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドPfizer Limited トロポミオシン関連キナーゼ阻害剤
EP2903989A1 (de) 2012-10-04 2015-08-12 Pfizer Limited Pyrrolo-[2,3-d-]pyrimidin-tropomyosin-vermittelte kinasehemmer
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
CN104837839A (zh) 2012-11-08 2015-08-12 辉瑞公司 作为多巴胺d1配体的杂芳族化合物
US20150291625A1 (en) 2012-11-08 2015-10-15 Pfizer Inc. Heteroaromatic Compounds and their Use as Dopamine D1 Ligands
JP2015536991A (ja) 2012-11-09 2015-12-24 セルジーン コーポレイション 骨量の減少の治療方法
JP6235603B2 (ja) 2012-11-15 2017-11-22 ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSAPIOTEC GmbH 消炎性および/または免疫抑制性活性成分としてのデルフィニジン複合体
CN104837836B (zh) 2012-11-21 2018-07-03 拉夸里亚创药株式会社 多晶型物
CA2889906A1 (en) 2012-11-29 2014-06-05 Sunovion Pharmaceuticals Inc. Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
JP6039100B2 (ja) 2012-12-03 2016-12-07 ファイザー・インク 新規選択的アンドロゲン受容体モジュレーター
EP2931287B1 (de) 2012-12-11 2017-10-04 Sapiotec GmbH Delphinidin zur bekämpfung von melanomzellen
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
KR20200143739A (ko) 2012-12-20 2020-12-24 사렙타 쎄러퓨틱스 인코퍼레이티드 근위축증을 치료하기 위한 개선된 엑손 스키핑 조성물
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
CA2896871A1 (en) 2012-12-31 2014-07-03 Kerry L. Spear Heterocyclic compounds and methods of use thereof
CA2935495C (en) 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
BR112015018882B1 (pt) 2013-02-19 2021-09-14 Novartis Ag Derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
PL3431475T3 (pl) 2013-02-21 2021-09-13 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EA035882B1 (ru) 2013-03-14 2020-08-27 Сарепта Терапьютикс, Инк. Антисмысловые олигонуклеотиды, обеспечивающие пропуск экзонов, для лечения мышечной дистрофии
DK2970964T3 (en) 2013-03-14 2019-04-01 Sarepta Therapeutics Inc EXON SKIPPING COMPOSITIONS FOR TREATMENT OF MUSCLE DYROPHY
EP3693021A1 (de) * 2013-03-14 2020-08-12 Allergan, Inc. Zusammensetzung mit verzögerter freisetzung und verfahren zur stabilisierung von proteinen während des herstellungsverfahrens
BR112015022998A2 (pt) 2013-03-15 2017-11-14 Sarepta Therapeutics Inc composições melhoradas para o tratamento de distrofia muscular
EP2784083A1 (de) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
AU2014248263A1 (en) 2013-04-02 2015-10-15 Celgene Corporation Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
EP2792360A1 (de) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
EP2815749A1 (de) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
MD20150122A2 (ro) 2013-06-27 2016-05-31 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
CA2916033C (en) 2013-07-08 2022-08-23 Abbvie Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
GB201312737D0 (en) * 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2015092610A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2015106012A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
CN103694376B (zh) * 2014-01-10 2016-04-13 凯莱英医药集团(天津)股份有限公司 一种制备磺丁基醚-β-环糊精的方法
WO2015109037A1 (en) 2014-01-15 2015-07-23 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3094629B1 (de) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idin-derivate und zusammensetzungen davon zur hemmung der aktivität von shp2
WO2015107493A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
EP2913050A1 (de) 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
EP3119744B1 (de) 2014-03-18 2019-03-06 Algiax Pharmaceuticals GmbH 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamidderivate
EP3131891A1 (de) 2014-04-15 2017-02-22 Pfizer Inc. Tropomysin-verwandte kinaseinhibitoren mit einer 1h-pyrazol- sowie pyrimidineinheit
WO2015162516A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
KR20160142401A (ko) 2014-04-25 2016-12-12 화이자 인코포레이티드 도파민 d1 리간드로서 헤테로방향족 화합물 및 이의 용도
US9868744B2 (en) 2014-04-25 2018-01-16 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
CA2946990A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heterocyclic compounds and their use as dopamine d1 ligands
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
EP3140298A1 (de) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-assoziierte kinaseinhibitoren
CN106459048A (zh) 2014-05-14 2017-02-22 辉瑞公司 吡唑并吡啶类和吡唑并嘧啶类
EP3143019B1 (de) 2014-05-15 2020-12-16 Pfizer Inc Kristalline form von 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isochinolin-1-carbonitril
KR102471082B1 (ko) 2014-05-20 2022-11-25 라퀄리아 파마 인코포레이티드 벤즈이소옥사졸 유도체염
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
JP2017516803A (ja) 2014-05-30 2017-06-22 ファイザー・インク ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
CN106572997A (zh) 2014-05-30 2017-04-19 辉瑞公司 作为选择性雄激素受体调节剂的腈衍生物
ES2664810T3 (es) 2014-06-12 2018-04-23 Pfizer Limited Derivados de imidazopiridazina como moduladores de la actividad del receptor GABAA
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
CR20160574A (es) 2014-06-17 2017-02-23 Pfizer Compuestos de dihidroisoquinolinona sustituida
WO2015195448A1 (en) 2014-06-18 2015-12-23 Eli Lilly And Company Transdermal formulations of pergolide and uses thereof
ES2843973T3 (es) 2014-06-27 2021-07-21 Celgene Corp Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
TWI568365B (zh) * 2014-07-22 2017-02-01 蘇廷弘 抑菌複合物及其製造方法
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
HUE063851T2 (hu) * 2014-08-22 2024-02-28 Cydex Pharmaceuticals Inc Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására
PL3182996T3 (pl) 2014-08-22 2023-04-17 Celgene Corporation Sposoby leczenia szpiczaka mnogiego związkami immunomodulującymi w kombinacji z przeciwciałami
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
WO2016044433A2 (en) 2014-09-16 2016-03-24 Biopharma Works Metformin derivatives
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
ES2746839T3 (es) 2014-12-18 2020-03-09 Pfizer Derivados de pirimidina y triazina y su uso como inhibidores de AXL
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
EP3556376A1 (de) 2015-01-22 2019-10-23 Phytoplant Research S.L. Verfahren zur reinigung von cannabinoiden, zusammensetzungen und kits dafür
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
PL3253208T3 (pl) 2015-02-02 2021-11-08 Mei Pharma, Inc. Terapie kombinowane do zastosowania w leczeniu nowotworu piersi
IL252848B1 (en) 2015-02-06 2024-03-01 Marinus Pharmaceuticals Inc Intravenous Genaxolone Formulations and Their Use in the Treatment of Epileptic Seizures and Other Seizure Disorders
TN2017000357A1 (en) 2015-02-24 2019-01-16 Pfizer Substituted nucleoside derivatives useful as anticancer agents
CA2979527A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease
CA2980170A1 (en) 2015-03-19 2016-09-22 Cydex Pharmaceuticals, Inc. Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
TW201642857A (zh) 2015-04-06 2016-12-16 西建公司 以組合療法治療肝細胞癌
NL2014614B1 (en) 2015-04-10 2017-01-25 Pld Biochemistry B V Method and means for increasing antibodies against Borrelia burgdorferi and increasing antigen of Borrelia burgdorferi.
WO2016195476A1 (en) 2015-05-29 2016-12-08 Erasmus University Medical Center Rotterdam Treatment of cardiac arrhythmias
JP6878316B2 (ja) 2015-06-19 2021-05-26 ノバルティス アーゲー Shp2の活性を阻害するための化合物および組成物
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
CN107922388B (zh) 2015-06-19 2020-12-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
SI3313818T1 (sl) 2015-06-26 2024-03-29 Celgene Corporation Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
EP3316888A1 (de) 2015-07-02 2018-05-09 Celgene Corporation Kombinationstherapie zur behandlung von hämatologischen krebserkrankungen und soliden tumoren
WO2017007805A1 (en) 2015-07-09 2017-01-12 Gilead Sciences, Inc. Intravenous formulations of a late sodium current inhibitor
BR112018000041A2 (pt) 2015-07-31 2018-09-04 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
US20190054113A1 (en) 2015-09-30 2019-02-21 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
CA3006865A1 (en) 2015-11-30 2017-06-08 Glaxosmithkline Intellectual Property (No.2) Limited Formulations for intravenous injection of danirixin
US10538523B2 (en) 2015-12-10 2020-01-21 Pfizer Limited 4-(biphen-3-yl)-1H-pyrazolo[3,4-c]pyridazine derivatives of formula (I) as GABA receptor modulators for use in the treatment of epilepsy and pain
SG11201805331QA (en) 2015-12-24 2018-07-30 Takeda Pharmaceuticals Co Cocrystal, production method thereof, and medicament containing cocrystal
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
EP3399968B8 (de) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selektive inhibitoren von klinisch wichtigen mutanten der egfr-tyrosin-kinase
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
SG11201805202VA (en) 2016-01-15 2018-07-30 Pfizer 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS
SI3411047T1 (sl) * 2016-02-04 2021-09-30 Czap Research And Development, Llc Sredstva za nadzorovano sproščeni in stratificirani kompleks vključitve ciklodekstrina
MA43815A (fr) 2016-03-08 2021-04-07 Sage Therapeutics Inc Stéroïdes neuroactifs, compositions, et leurs utilisations
CN108884445A (zh) 2016-03-09 2018-11-23 北京智康博药肿瘤医学研究有限公司 肿瘤细胞悬浮培养物和相关方法
AU2017240609B2 (en) * 2016-03-31 2021-07-15 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
KR102329187B1 (ko) 2016-04-29 2021-11-22 사렙타 쎄러퓨틱스, 인코퍼레이티드 인간 lmna를 표적화하는 올리고뉴클레오타이드 유사체
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
ES2810852T3 (es) 2016-06-14 2021-03-09 Novartis Ag Compuestos y composiciones para inhibir la actividad de shp2
JP2019525742A (ja) 2016-06-30 2019-09-12 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマー
WO2018015465A1 (en) * 2016-07-22 2018-01-25 Ecole Polytechnique Federale De Lausanne (Epfl) Virucidal compounds and uses thereof
EA201990399A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения, композиции и их применение
CN116283877A (zh) 2016-07-29 2023-06-23 赛诺维信制药公司 化合物、组合物及其用途
EP3491005A1 (de) 2016-07-29 2019-06-05 Pfizer Inc Cyclische peptide als c5-a-rezeptorantagonisten
JP2019524816A (ja) 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドOvid Therapeutics, Inc. てんかん性障害の処置のための方法および組成物
GEP20217234B (en) 2016-08-15 2021-03-25 Pfizer Pyridopyrimdinone cdk2/4/6 inhibitors
EP3503885B1 (de) * 2016-08-19 2022-03-23 Foresee Pharmaceuticals Co., Ltd. Pharmazeutische zusammensetzungen und verfahren zur verwendung
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CA3040155C (en) 2016-10-11 2024-01-16 Euro-Celtique S.A. Compound for use in the treatment of hodgkin lymphoma
TW201828938A (zh) 2016-11-18 2018-08-16 德商艾庫里斯抗感染治療有限公司 以改質的環糊精及酸化劑為基底之經脒取代之β-內醯胺化合物的新穎調配物,其製備方法及作為抗微生物醫藥組合物之用途
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
AU2017382773A1 (en) 2016-12-19 2019-08-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
WO2018118627A1 (en) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
BR112019012647A2 (pt) 2016-12-19 2019-11-19 Sarepta Therapeutics Inc conjugados de oligômero de salto de éxon para distrofia muscular
WO2018118791A2 (en) 2016-12-20 2018-06-28 Oligomerix, Inc. Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
EP3571191A1 (de) 2017-01-20 2019-11-27 Pfizer Inc 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamatderivate als magl-inhibitoren
EP3571202B1 (de) 2017-01-23 2021-06-30 Pfizer Inc. Heterocyclische spiro-verbindungen als magl-inhibitoren
WO2018140671A1 (en) 2017-01-27 2018-08-02 Celgene Corporation 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
US11129807B2 (en) 2017-02-16 2021-09-28 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
MX2019011286A (es) 2017-03-26 2019-12-19 Takeda Pharmaceuticals Co Carboxamidas heteroaromaticas sustituidas de piperidinilo y piperazinilo como moduladores de gpr6.
JP2020517638A (ja) 2017-04-20 2020-06-18 エータイアー ファーマ, インコーポレイテッド 肺の炎症を治療するための組成物および方法
US20180318249A1 (en) 2017-05-03 2018-11-08 Cydex Pharmaceuticals, Inc. Composition containing cyclodextrin and busulfan
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
SG11201912397RA (en) 2017-06-22 2020-01-30 Curadev Pharma Ltd Small molecule modulators of human sting
EP3644999B1 (de) * 2017-06-30 2022-12-14 Celgene Corporation Zusammensetzungen und verfahren zur verwendung von 2-(4-chlorphenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoracetamid
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
EA202090414A1 (ru) 2017-08-02 2020-05-28 Суновион Фармасьютикалз Инк. Соединения и их применение
EP3692048A4 (de) 2017-08-30 2021-10-20 Beijing Xuanyi Pharmasciences Co., Ltd. Cyclische di-nukleotide als stimulator von modulatoren von interferon-genen
EP3681879A1 (de) 2017-09-11 2020-07-22 Krouzon Pharmaceuticals, Inc. Allosterische octahydrocyclopenta[c]pyrrolinhibitoren von shp2
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
JP2020536060A (ja) 2017-09-28 2020-12-10 サレプタ セラピューティクス, インコーポレイテッド 筋ジストロフィーを処置するための併用療法
WO2019067981A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. POLYTHERAPIES FOR TREATING MUSCLE DYSTROPHY
EP3687519A1 (de) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Kombinationstherapien zur behandlung von muskeldystrophie
CN111788171A (zh) 2018-01-29 2020-10-16 菲拓普兰特研究公司 使用液:液色谱法纯化大麻素的方法
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
SG11202008398XA (en) 2018-03-01 2020-09-29 Takeda Pharmaceuticals Co Piperidinyl-3-(aryloxy)propanamides and propanoates
US10538542B2 (en) 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
UA126177C2 (uk) 2018-04-26 2022-08-25 Пфайзер Інк. Похідні 2-амінопіридину або 2-амінопіримідину як інгібітори циклінзалежної кінази
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
CN112218627B (zh) 2018-05-30 2024-04-16 康维尔特制药有限公司 前药及其在医学上的应用
EP4241563A3 (de) 2018-06-01 2023-11-15 Bayer CropScience LP Stabilisierte fungizide zusammensetzung mit cyclodextrin
EP3806868A4 (de) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. Exon-skipping-oligomere für muskeldystrophie
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
CA3106510A1 (en) 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
TW202020153A (zh) 2018-07-27 2020-06-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
MX2021006095A (es) 2018-11-29 2021-07-06 Pfizer Pirazoles como moduladores de hemoglobina.
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
KR20210104759A (ko) 2018-12-13 2021-08-25 사렙타 쎄러퓨틱스 인코퍼레이티드 근 이영양증을 위한 엑손 스키핑 올리고머 접합체
JP2022518147A (ja) 2019-01-03 2022-03-14 アンダードッグ・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン二量体、それらの組成物、及びそれらの使用
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
EP3914597A1 (de) 2019-01-23 2021-12-01 Pfizer Inc. Polymorphe form eines monophosphathydratsalzes eines bekannten tetrahydroisochinolinderivats
JP7094456B2 (ja) 2019-01-31 2022-07-01 ファイザー・インク Cdk2阻害剤
US11529357B2 (en) 2019-02-01 2022-12-20 H. Lundbeck A/S Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine
AU2020236225A1 (en) 2019-03-14 2021-09-16 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
WO2020198053A1 (en) 2019-03-22 2020-10-01 Takeda Pharmaceutical Company Limited 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
WO2020198268A1 (en) 2019-03-28 2020-10-01 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy with casimersen
WO2020214763A1 (en) 2019-04-18 2020-10-22 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
CA3137584A1 (en) 2019-04-29 2020-11-05 Solent Therapeutics, Llc 3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
WO2020257489A1 (en) 2019-06-19 2020-12-24 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
JP2022542144A (ja) 2019-07-25 2022-09-29 キュラデブ ファーマ ピーブイティー. リミテッド アセチル補酵素aシンテターゼ短鎖2(acss2)の小分子阻害剤
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
US20230000997A1 (en) 2019-08-06 2023-01-05 L.E.A.F. Holdings Group Llc Processes of preparing polyglutamated antifolates and uses of their compositions
MX2022003177A (es) 2019-09-16 2022-04-06 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol.
BR112022005463A2 (pt) 2019-09-25 2022-06-14 Pfizer Moduladores poli-heterocíclicos de sting (estimulador de genes de interferon)
US20210145816A1 (en) 2019-11-15 2021-05-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
EP4069245A1 (de) 2019-12-02 2022-10-12 Celgene Corporation Verfahren zur behandlung von krebs
KR20220134529A (ko) 2019-12-06 2022-10-05 마리누스 파마슈티컬스 인코포레이티드 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론
CA3166358A1 (en) 2020-02-12 2021-08-19 Monali BANERJEE Small molecule sting antagonists
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
PE20230323A1 (es) 2020-05-01 2023-02-22 Pfizer Compuestos de azalactama como inhibidores de hpk1
PE20231375A1 (es) 2020-05-04 2023-09-07 Takeda Pharmaceuticals Co Derivados de n-(piperidin-4-il)benzamida de accion luminal
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Her2突變抑制劑
WO2022013692A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
WO2022013691A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorph of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
AU2022250712A1 (en) 2021-03-31 2023-10-05 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
EP4320121A2 (de) 2021-04-07 2024-02-14 LifeArc 2,4-diaminopyrimidinderivate als ulk1/2-inhibitoren und deren verwendung
EP4359082A1 (de) 2021-06-26 2024-05-01 Array BioPharma Inc. Her2-mutationsinhibitoren
WO2023015240A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Tricyclic fused pyrimidine compounds for use as her2 inhibitors
AU2022325543A1 (en) 2021-08-11 2024-02-15 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
TW202321231A (zh) 2021-08-11 2023-06-01 印度商裘拉德製藥私人有限公司 作為sting拮抗劑之小分子尿素衍生物
EP4162933A1 (de) 2021-10-08 2023-04-12 Algiax Pharmaceuticals GmbH Verbindung zur behandlung von nicht-alkoholischer fettlebererkrankung und verwandten erkrankungen
WO2023099072A1 (en) 2021-12-01 2023-06-08 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Compounds
WO2023178230A1 (en) 2022-03-17 2023-09-21 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
WO2023187677A1 (en) 2022-03-30 2023-10-05 Takeda Pharmaceutical Company Limited N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
TW202345838A (zh) 2022-04-07 2023-12-01 日商武田藥品工業股份有限公司 稠合噠嗪衍生物
US20240109915A1 (en) 2022-07-29 2024-04-04 Pfizer Inc. Novel acc inhibitors
WO2024033845A1 (en) 2022-08-10 2024-02-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2024073570A1 (en) 2022-09-28 2024-04-04 Altos Labs, Inc. Expression of regeneration factors in aged/senescent cells
WO2024074827A1 (en) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited New treatments for pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
JPS503362B1 (de) * 1970-06-10 1975-02-04
EP0056995B1 (de) * 1981-01-23 1986-03-26 The Wellcome Foundation Limited Chemischer Komplex
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
EP0146841A3 (de) * 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
DE3477929D1 (en) * 1983-12-17 1989-06-01 Hoechst Ag Beta-cyclodextrin and process for its preparation
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPH0651725B2 (ja) * 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
JPS6327440A (ja) * 1986-07-18 1988-02-05 Sanraku Inc グルコシル化分岐シクロデキストリン含有組成物
US4808232A (en) * 1986-12-08 1989-02-28 American Maize-Products Company Separation and purification of cyclodextrins
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride

Also Published As

Publication number Publication date
AU646020B2 (en) 1994-02-03
RU2099354C1 (ru) 1997-12-20
EP0512050A1 (de) 1992-11-11
WO1991011172A1 (en) 1991-08-08
AU7236491A (en) 1991-08-21
CA2074186C (en) 2001-04-03
JP2722277B2 (ja) 1998-03-04
DE69130165T2 (de) 1999-04-29
EP0512050A4 (en) 1993-04-21
KR0166088B1 (ko) 1999-01-15
US5134127A (en) 1992-07-28
KR920703008A (ko) 1992-12-17
CA2074186A1 (en) 1991-07-24
ATE170742T1 (de) 1998-09-15
EP0512050B1 (de) 1998-09-09
JPH05504783A (ja) 1993-07-22

Similar Documents

Publication Publication Date Title
DE69130165D1 (de) Cyclodextrinderivate mit erhöhter wasserlöslichkeit sowie deren verwendung
ATE217325T1 (de) Cyclodextrinderivate mit erhöhter wasserlösichkeit und deren verwendung
ATE109002T1 (de) Wasserlösliche antineoplastische taxolderivate.
YU17092A (sh) Derivati 2,4-diaminohinazolina
DK0792288T3 (da) Konjugater af BDNF og NT-3 med en vandopløselig polymer
IT1303808B1 (it) Trattamenti di superfici con derivati bifunzionali diperfluoropolieteri.
IT9048430A0 (it) Derivati di isoindolo e loro sali, procedimenti per produrli ed agenteantitumore che li contiene.
DE69204909T2 (de) Amino-Urazilderivate, deren Herstellung und Verwendung.
ITTO910567A1 (it) Derivati carbostirilici.
YU39992A (sh) Derivati 2,4-diaminopirimidina
TR199600355A2 (tr) Yakin mesafe/yakinlik detektörü.
TR199700354A3 (tr) Karbohidrat türevleri.
DE69114601D1 (de) Phenytoinderivate.
TW350983B (en) Wafer edge deposition elimination
DE69114391D1 (de) Breitbandverstärker mit getrennten Ausgängen.
DE69801959T2 (de) Bromierte 1,3-Dimethyl-3-phenyl-1-(2-methyl-2-phenylpropyl)-indan-Derivate sowie deren Herstellungsmethode
DE69917440D1 (de) 5-imino-13-deoxy-antracyclin-derivate, ihre verwendung sowie verfahren zu deren herstellung
BA96113A (bs) Derivati 12,11113-epoksi-tilozina i postupci za njihovo dobivanje
NO901829D0 (no) Overflatehydratiserte poroese polyakrylonitrilsubstater saasom kulederivater derav, fremgangsmaater for fremstilling og for anvendelse derav.
ITRM910976A0 (it) Procedimento e tecnica per produrre la fotografia e i suoi derivati per non vedenti e per sordociechi.
ITMI962497A0 (it) Derivati 2, 3, 4, 7-tetraidropiridoindazolo-(1,4)benzodiazepinici aventi attivita' antitumorale
TR26486A (tr) H sekilli önceden olusturulan baglanti mafsali.
ITMI940683A1 (it) Derivati di benzo (b) decalin-5, 10-dioni-2, 3, 4-alfa, 10-alfa-deidro ad attivita' antitumorale
FR2654447B1 (fr) Joint de dilatation, en particulier joint de trottoir.
IT1311497B1 (it) Derivati polinucleari di ti(v) con leganti 4-acil-5-pirazolonati adattivita' antitumorale e procedimento per la loro produzione.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition